Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2007 4
2008 4
2009 2
2010 3
2011 10
2012 8
2013 11
2014 12
2015 13
2016 5
2017 12
2018 9
2019 5
2020 2
2021 9
2022 9
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

105 results

Results by year

Filters applied: . Clear all
Page 1
Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study.
Lesokhin A, LeBlanc R, Dimopoulos MA, Capra M, Carlo-Stella C, Karlin L, Castilloux JF, Forsberg P, Parmar G, Tosikyan A, Pour L, Ribrag V, Ribolla R, Abdallah AO, Le Roux N, Dong L, van de Velde H, Mayrargue L, Lépine L, Macé S, Moreau P. Lesokhin A, et al. Among authors: van de velde h. Cancer Med. 2023 May;12(9):10254-10266. doi: 10.1002/cam4.5753. Epub 2023 Mar 3. Cancer Med. 2023. PMID: 36866838 Free PMC article. Clinical Trial.
Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.
Spicka I, Moreau P, Martin TG, Facon T, Martinez G, Oriol A, Koh Y, Lim A, Mikala G, Rosiñol L, Yağci M, Cavo M, Risse ML, Asset G, Macé S, van de Velde H, Yong K. Spicka I, et al. Among authors: van de velde h. Eur J Haematol. 2022 Nov;109(5):504-512. doi: 10.1111/ejh.13835. Epub 2022 Aug 18. Eur J Haematol. 2022. PMID: 35871357 Free PMC article.
Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA.
Martin T, Richardson PG, Facon T, Moreau P, Perrot A, Spicka I, Bisht K, Inchauspé M, Casca F, Macé S, Van de Velde H, Suzuki K. Martin T, et al. Among authors: van de velde h. Haematologica. 2022 Oct 1;107(10):2485-2491. doi: 10.3324/haematol.2022.280660. Haematologica. 2022. PMID: 35734925 Free PMC article. No abstract available.
Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma.
Martin T, Mikhael J, Hajek R, Kim K, Suzuki K, Hulin C, Garg M, Quach H, Sia H, George A, Konstantinova T, Risse ML, Asset G, Macé S, van de Velde H, Moreau P. Martin T, et al. Among authors: van de velde h. Blood Adv. 2022 Aug 9;6(15):4506-4515. doi: 10.1182/bloodadvances.2021006713. Blood Adv. 2022. PMID: 35594559 Free PMC article. Clinical Trial.
Exposure-response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma.
Rachedi F, Koiwai K, Gaudel-Dedieu N, Sebastien B, Thai HT, Brillac C, Fau JB, Nguyen L, van de Velde H, Veyrat-Follet C, Semiond D. Rachedi F, et al. Among authors: van de velde h. CPT Pharmacometrics Syst Pharmacol. 2022 Jun;11(6):766-777. doi: 10.1002/psp4.12789. Epub 2022 Apr 17. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 35355430 Free PMC article. Clinical Trial.
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.
Schjesvold F, Richardson PG, Facon T, Alegre A, Spencer A, Jurczyszyn A, Sunami K, Frenzel L, Min CK, Guillonneau S, Lin PL, Le-Guennec S, Campana F, Van de Velde H, Bensfia S, Bringhen S. Schjesvold F, et al. Among authors: van de velde h. Haematologica. 2022 Mar 1;107(3):774-775. doi: 10.3324/haematol.2021.279160. Haematologica. 2022. PMID: 35229573 Free PMC article. No abstract available.
SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma.
Kassem S, Diallo BK, El-Murr N, Carrié N, Tang A, Fournier A, Bonnevaux H, Nicolazzi C, Cuisinier M, Arnould I, Sidhu SS, Corre J, Avet-Loiseau H, Teillaud JL, van de Velde H, Wiederschain D, Chiron M, Martinet L, Virone-Oddos A. Kassem S, et al. Among authors: van de velde h. Blood. 2022 Feb 24;139(8):1160-1176. doi: 10.1182/blood.2021012448. Blood. 2022. PMID: 35201323 Free article.
105 results